Latest news

Clinical Update – Debio 9902 SR (ZT-1) for Alzheimer Patients – Debiopharm Starts Tablet Formulation Bridging Study under IN

Debiopharm moves towards a new 6-month formulation of Decapeptyl® to further help prostate cancer patients

Debiopharm investit pour les médicaments innovants de demain – Inauguration de Campus “après-demain”, son site de développement et de production

Debiopharm and EPFL Sign Research Project Agreement to Identify Inhibitors of Signalling Pathways Controlling Cell Fate For Cancer Treatment

Doctor Manel Esteller Receives the Debiopharm Life Sciences Award For his Outstanding Research in Epigenetic Oncology

Le “Prix Debiopharm/Valais pour les Sciences de la Vie” honore un chimiste valaisan pour son procédé électrochimique novateur

Debiopharm Signs License Agreement for Marketing of Salvacyl®/Moapar 3-month for Sexual Deviations

Clinical Update – Debio 025 in Hepatitis C – Presentation of Phase IIa Efficacy Results

Debiopharm and Airmid Sign Option and License Agreement for the Development of Debio 0824, an ShK Peptide for Autoimmune Disorders